NCT06514599Completed
CRP, Procalcitonin and Pro-BNP as Diagnostic and Prognostic Markers in AECOPD
Comparison of The Efficacy of CRP, Procalcitonin and Pro-BNP as Diagnostic and Prognostic Markers in AECOPD
Source: ClinicalTrials.gov · Last updated 23 Jul 2024
Brief summary (registry, in English)
Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) are one of the chief causes for admission to Emergency Department. AECOPD is a significant cause for mortality and morbidity worldwide. Emergency Medicine Physicians frequently manage these patients. Predicting the severity and possible prognosis of AECOPD is an important task for Emergency Medicine Physicians as treatment options and aggressiveness may depend on these predictions. In our study we aimed to compare different biomarkers such as Procalcitonin, Pro-Brain Natriuretic Peptide (Pro-BNP) and C-Reactive Protein (CRP) on their efficacy at predicting the severity and prognosis of AECOPD. We analyzed the data of the selected 196 patients with the diagnosis AECOPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 guide who were admitted to our Emergency Department between 15/02/2023 and 15/02/2024.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 196 (actual)
- First submitted
- 10 Jul 2024
- Start date
- 15 Feb 2023
- Primary completion date
- 15 Feb 2024
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Diseases
- COPD
- NCT number
- NCT06514599
What you commit to
- Study type: Observational
- Participants enrolled: 196
- From 15 Feb 2023 to the primary completion date, 15 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- being younger than 18 years old
Other
- not having been diagnosed with COPD by a specialist, not fulfilling the definition of an exacerbation set by GOLD 2024 guide
- refusing to sign the consent and approval form.
Who the study is looking for
- being older than 18 years old
- having been diagnosed with COPD by a specialist
- fulfilling the definition of an exacerbation set by GOLD 2024 guide which are having increased dyspnea, cough and sputum in a timespan of less than 14 days with or without tachypnea and tachycardia
- having signed the consent and approval form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ministry of Health, University of Health Sciences, İstanbul Kanuni SUltan Suleyman TRaining and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.